Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IBI363 + Chemotherapy”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Looking for participantsNCT07325630
What this trial is testing

Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer

Who this might be right for
IBI363 + Chemotherapy
Zhejiang Cancer Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT07408635
What this trial is testing

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

Who this might be right for
Unresectable Stage III Non-small Cell Lung CancerCarcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China 43
Early research (Phase 1)Looking for participantsNCT06610799
What this trial is testing

Study of IBI363 in Patients with Advanced First-line Gastric Cancer

Who this might be right for
IBI363 + Chemotherapy
Xiangdong Cheng 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07342725
What this trial is testing

Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer Metastatic
Ruijin Hospital 48
Testing effectiveness (Phase 2)Looking for participantsNCT07122687
What this trial is testing

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd. 170
Large-scale testing (Phase 3)Looking for participantsNCT07217301
What this trial is testing

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

Who this might be right for
iO Resistant sqNSCLC
Fortvita Biologics (USA)Inc. 600